TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma

Liu, Bo-wen; Wang, Xiang-yun; Cao, Jin-ling; Chen, Lu-lu; Wang, Yi-lei; Zhao, Bing-qian; Zhou, Jia; Shen, Zhi-fa

doi:10.1038/s42003-022-03788-w

Download PDF

Article
Open access
Published: 13 August 2022

TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma

Bo-wen Liu ORCID: orcid.org/0000-0002-7891-1934¹^na1^na2,
Xiang-yun Wang¹^na1,
Jin-ling Cao¹^na1,
Lu-lu Chen¹,
Yi-lei Wang¹,
Bing-qian Zhao¹,
Jia Zhou¹ &
…
Zhi-fa Shen ORCID: orcid.org/0000-0003-4707-8772¹^na2

Communications Biology volume 5, Article number: 816 (2022) Cite this article

2024 Accesses
6 Citations
1 Altmetric
Metrics details

Subjects

Abstract

TAR DNA-Binding Protein 43 (TDP-43) has been well studied in neurodegenerative diseases, but its potential role in malignance is still unclear. Here, we demonstrate that TDP-43 contributes to the suppression of apoptosis by facilitating lipid metabolism in hepatocellular carcinoma (HCC). In HCC cells, TDP-43 is able to suppress apoptosis while deletion of it markedly induces apoptosis. RNA-sequencing identifies the lipid metabolism gene abhydrolase domain containing 2 (ABHD2) as the target gene of TDP-43. Tissue microarray analysis shows the positive correlation of TDP-43 and ABHD2 in HCC. Mechanistically, TDP-43 binds with the UG-rich sequence1 of ABHD2 3’UTR to enhance the mRNA stability of ABHD2, thereby upregulating ABHD2. Afterwards, TDP-43 promotes the production of free fatty acid and fatty acid oxidation-originated reactive oxygen species (ROS) in an ABHD2-dependent manner, so as to suppress apoptosis of HCC. Our findings provide insights into the mechanism of HCC progression and reveal TDP-43/ABHD2 as potential targets for the precise treatment of HCC.

LINC01468 drives NAFLD-HCC progression through CUL4A-linked degradation of SHIP2

Article Open access 07 November 2022

Fatty-acid-induced FABP5/HIF-1 reprograms lipid metabolism and enhances the proliferation of liver cancer cells

Article Open access 30 October 2020

LncRNA HEPFAL accelerates ferroptosis in hepatocellular carcinoma by regulating SLC7A11 ubiquitination

Article Open access 25 August 2022

Introduction

Hepatocellular carcinoma (HCC), one of the common malignant tumors around the world^1,2, has seriously endangered human life and health for many years. The pathogenesis of HCC is complicated, it involves a variety of processes, such as chronic inflammation, liver fibrosis and oncogene dysregulation^2,3. The dysregulation of oncogene expression always induces the disorder of the physiological state of cell, which results in excessive proliferation and suppressive apoptosis, accelerating the malignant progression of HCC⁴. Therefore, clarifying the mechanism of initiation and development is crucial for the targeted therapy in HCC.

Transactivation (TAR) DNA-binding protein (TARDBP), also known as TDP-43^5,6, was originally identified as a DNA-binding protein capable of regulating human immunodeficiency virus 1 gene expression^7,8. Later studies found that TDP-43, encoded by the tardbp gene, is a highly conserved DNA/RNA-binding protein. In the nucleus, TDP-43 can bind to RNA and play an important role in mRNA transcription, splicing, nuclear transport and stability^5,9. In the cytoplasm, TDP-43 forms RNP ribonucleoprotein granules that regulate mRNA transport and promote the production of non-coding RNAs such as miRNA^10,11. TDP-43 has been focused because of its vital role in neurodegenerative diseases, such as amyotrophic lateral sclerosis and Alzheimer’s disease^12,13. Recently, it has been discovered that TDP-43 is closely correlated with the progression of malignant tumors. Studies have shown that TDP-43 is dysregulated in breast cancer, lung cancer, melanoma and other malignant tumors^14,15,16. In breast tumor, TDP-43 can interact with serine and arginine rich splicing factor 3 to modulate the selective splicing of downstream targets PAPR3 and NUMB mRNA, thereby promoting tumor proliferation and metastasis¹⁴. In lung cancer cells, TDP-43 enhances the mRNA stability of FasL by interacting with FasL mRNA, thereby mediating apoptosis and finally inhibiting the progression of lung cancer¹⁶.

Notably, a previous study shows that TDP-43 elevates the expression of the platelet isoform of phosphofructokinase, a rate-limiting enzyme of glycolysis, to promote cell growth in HCC¹⁷. This evidence indicates the potential role of TDP-43 in modulating cell metabolism in HCC. Abnormal metabolism is a common hallmark of cancer cells; especially glucose metabolism and lipid metabolism, cancer cells often reprogram these metabolic pathways to meet the energy needs of overgrowth and to resist apoptosis¹⁸. Liver is an important place for lipid metabolism, and plays a vital role in the absorption, synthesis, decomposition, and transport of lipids¹⁹. lipid metabolism disorder usually appears during the occurrence and development of HCC^20,21. However, whether TDP-43 has an effect on lipid metabolism in the progression of HCC and the underlying mechanism are still unknown.

In the present study, we uncover that the expression of TDP-43 is negatively related to the overall survival and relapse-free survival of HCC. TDP-43 suppresses the cell apoptosis of HCC through the lipid metabolism-related gene ABHD2. Molecular mechanism investigation reveals that TDP-43 can bind to the 3ʹUTR of ABHD2 mRNA and enhance the stability of ABHD2 mRNA, thereby upregulating the expression of ABHD2. TDP-43 was able to promote the production of free fatty acid (FFA) and fatty acid oxidation-originated reactive oxygen species (ROS) in an ABHD2-dependent manner, thereby promoting proliferation and inhibiting apoptosis in HCC cells. Our study provides a potential target for the precise treatment of HCC.

Results

TDP-43 inhibits apoptosis and promotes proliferation in HCC cells

Firstly, we detected the expression levels of TDP-43 in different HCC cell lines by qRT-PCR and Western blot assays. The results in these cell lines showed that the expression of TDP-43 was weakest in Huh-7 cell line while abundantly in SMMC-7721 and MHCC97H cell lines (Supplementary Fig. 1a, b). Accordingly, we selected Huh-7 cells to overexpress TDP-43 and selected SMMC-7721 and MHCC97H cells to knock down TDP-43 in subsequent experiments. To explore the potential role of TDP-43 in HCC progression, we tested the effect of TDP-43 on cell proliferation by colony formation assay. Two different si-TDP-43 (termed as si-TDP-43#1 and si-TDP-43#2) were transiently transfected into SMMC-7721 and MHCC97H cells to specifically silence TDP-43 expression. The results showed that silence of TDP-43 obviously weakened the formation of colony in SMMC-7721 and MHCC97H cells (Fig. 1a, c). However, overexpression of TDP-43 in Huh-7 cells promoted the formation of colony (Fig. 1b, c). Then, we evaluated the effect of TDP-43 on apoptosis by Annexin V-FITC/PI double staining method. Silence of TDP-43 induced apoptosis in MHCC97H and SMMC-7721 cells, while TDP-43 overexpression efficiently suppressed apoptosis in Huh-7 cells (Fig. 1d–g). Next, we used MHCC97H cells to establish a TDP-43 stable-knockdown cell line (MHCC97H-KD-TDP-43) and its control cell line (MHCC97H-Control), and applied them in the subsequent studies. The expression levels of proliferation- and apoptosis-associated markers were evaluated by qRT-PCR and Western blot assay. The results displayed that TDP-43 upregulated the antiapoptotic gene Bcl-2 and proliferation marker Ki67. Meanwhile, TDP-43 downregulated the proapoptotic genes p53 and Bax (Fig. 1h, i, Supplementary Fig. 1c–e). Caspase3 is activated to form cleaved-caspase3 (C-caspase3), which is the vital terminal cleavage enzyme in apoptotic processes²². TDP-43 could negatively modulate the protein level of C-caspase3 (Fig. 1i). These findings demonstrate that TDP-43 prevents apoptosis and facilitates proliferation in HCC cells.

TDP-43 accelerates growth and inhibits apoptosis in liver tumor

In order to further verify the effect of TDP-43 on cell apoptosis and proliferation in HCC, we used MHCC97H-KD-TDP-43 and MHCC97H-Control cells to conduct subcutaneous tumorigenesis experiments in nude mice. The results revealed that the weight and volume of tumors in nude mice were markedly reduced when TDP-43 was silenced (Fig. 2a–c). No difference was observed in the body weights of mice among the two groups, suggesting that the mice remained healthy upon TDP-43 knockdown (Fig. 2d). Subsequently, we evaluated the expressions of Ki67, C-caspase3, p53 and Bcl-2 in tumor tissues by immunohistochemistry (IHC) staining. IHC data uncovered that knockdown of TDP-43 depressed the expression of Ki67 and Bcl-2; Conversely, the expression levels of C-caspase3 and p53 were increased followed by TDP-43 knockdown (Fig. 2e, f). These data were in accordance with the aforesaid data in vitro, further indicating the role of TDP-43 on cell apoptosis and proliferation. In addition, we used an online resource to analyze the association between TDP-43 and the prognosis of HCC patients. The results revealed that the higher the expression level of TDP-43, the shorter the overall survival and relapse-free survival (Fig. 2g, h). Meanwhile, analysis of GSE36376 indicated that the expression level of TDP-43 in HCC tissues was substantially higher than that in adjacent non-tumor tissues (Fig. 2i). Therefore, TDP-43 is strongly associated with the poor prognosis of HCC.

Lipid metabolism-related gene ABHD2 is identified as a target of TDP-43

To identify the downstream target genes of TDP-43, we performed high-throughput transcriptome sequencing (RNA-seq) and obtained the transcriptome expression profiles of MHCC97H-KD-TDP-43 cells and control cells. After knocking down TDP-43, the expressions of 1392 genes were increased and 1418 genes were decreased (Supplementary Fig. 2). The differentially expressed genes were displayed by a volcano plot and a hierarchical clustering heatmap (TOP100 of down-regulated genes) (Fig. 3a, b). GSEA analysis revealed that apoptosis was strongly responsive to the change in TDP-43 expression (Fig. 3c), suggesting that TDP-43 is closely related to apoptosis. This was consistent with our previous experimental results (Figs.1 and 2). KEGG pathway enrichment analysis was performed on the down-regulated genes, and the results showed that these genes might be more involved in metabolic pathways (Fig. 3d), especially in lipid metabolism pathways (Fig. 3e). To further confirm whether TDP-43 was related to metabolism, we screened all metabolism-related genes in down-regulated genes (TOP50) for expression verification. Interestingly, compared with other metabolism-related genes, the lipid metabolism-related gene, abhydrolase domain containing 2 (ABHD2) was the most considerably down-regulated after TDP-43 knockdown (Fig. 3f). This evidence was consistent with the analysis of the metabolic pathway in Fig. 3e. Thus, we get the conclusion that the lipid metabolism-related gene ABHD2 is identified as a downstream target of TDP-43.

TDP-43 is positively related to ABHD2 and increases ABHD2 expression in HCC

Next, we performed qRT-PCR and Western blot assay in different HCC cell lines to confirm the effect of TDP-43 on ABHD2 expression. Silence of TDP-43 efficiently decreased the expression of ABHD2, while TDP-43 overexpression obviously increased ABHD2 (Fig. 4a–d and Supplementary Fig. 3a, b). Meanwhile, the expression levels of ABHD2 in mice tumor tissues were determined by IHC staining assay. We found that TDP-43 deficiency could reduce the expression of ABHD2 in tumor tissues (Fig. 4e). Moreover, the gene correlation analysis from the online database GEPIA showed that the expression of TDP-43 and ABHD2 in HCC was highly correlated (Fig. 4f, g). To further verify the correlation between the expression of TDP-43 and ABHD2 in HCC tissues, we performed IHC staining on two consecutive sections of HCC tissue microarray. There were 32 cases of HCC tissues and paired non-tumor tissues in the tissue microarray. The result manifested that TDP-43 was positively related to ABHD2 in HCC tissues (Fig. 4h, i, and Supplementary Fig. 3c, Pearson’s chi-square independent test, χ^² = 61.41, P < 0.0001).

TDP-43 upregulates ABHD2 through enhancing the mRNA stability of ABHD2

Next, we aimed to elucidate the upregulation mechanism of ABHD2 mediated by TDP-43. TDP-43 is an RNA-binding protein, which can regulate the splicing, transport and stability of RNA⁵. Therefore, we wondered whether TDP-43 exerted a regulatory role by binding to ABHD2 mRNA. The RNA immunoprecipitation (RIP) assay in MHCC97H cells showed that TDP-43 could indeed bind to ABHD2 mRNA (Fig. 5a). To further explore whether TDP-43 regulates ABHD2 at the transcriptional or post-transcriptional level, we performed mRNA stability assays in different HCC cell lines. QRT-PCR results indicated that knockdown of TDP-43 could still downregulate the mRNA level of ABHD2 after time-dependently treated with transcription inhibitor Actinomycin-D (ActD) (Fig. 5b, c). This evidence uncovered the promotion of TDP-43 on ABHD2 mRNA stability.

Studies have shown that TDP-43 has a high affinity for UG-rich sequences, which can bind to them and regulate the maturation of pre-mRNA^23,24. After sequence analysis, we found there were two UG-rich sequences in the 3ʹUTR of ABHD2 mRNA. Therefore, we cloned the 3ʹUTR of ABHD2 mRNA and constructed it into a luciferase vector (pGL3-Control). The data showed that overexpression of TDP-43 could upregulate the luciferase activity of ABHD2 3ʹUTR, while TDP-43 silencing markedly inhibited the luciferase activity (Fig. 5d, e). Then, we separately deleted the two UG rich sequences in ABHD2 3ʹUTR (termed as Del-1 and Del-2, respectively; the former construction of ABHD2 3ʹUTR termed as WT) (Fig. 5f), and detected the activities of luciferase reporter. After overexpression of TDP-43, the luciferase activities of WT and Del-2 were increased; similarly, the luciferase activities of WT and Del-2 were decreased upon TDP-43 deletion (Fig. 5g, h). However, the luciferase activity of Del-1 did not change obviously no matter TDP-43 was knocked down or overexpressed (Fig. 5g, h). These above results indicate that TDP-43 binds to the UG-rich sequence 1 of ABHD2 3ʹUTR, enhances the stability of ABHD2 mRNA, and then upregulates its expression.

Lipid metabolism modulator ABHD2 contributes to the malignant behaviors of HCC

ABHD2, a member of α/β-hydrolase domain (ABHD) family, has the lipase serine nucleophilic motif GXSXG and can participate in lipid metabolism by exerting triacylglycerol lipase activity²⁵. Under the action of triacylglycerol lipase, triacylglycerols (TG) are hydrolyzed to produce fatty acids^26,27. Therefore, we examined the effects of ABHD2 on intracellular TG levels. The data displayed that deletion of ABHD2 obviously induced the accumulation of TG in SMMC-7721 and MHCC97H cells (Supplementary Fig. 4a, b). Meanwhile, the content of free fatty acid (FFA) was efficiently decreased after ABHD2 knockdown (Fig. 6a), indicating that ABHD2 can indeed serve as triacylglycerol lipase to promote the generation of fatty acid.

In the liver, mitochondrial β-oxidation is one of the major metabolic fates of FFAs, which will increase the production of ROS^26,28. Studies have shown that ROS is critical for cell survival, and small increases in ROS levels can lead to the activation of some proto-oncogenic pathways and facilitate cancer development^29,30. We examined the cellular ROS level and found that ABHD2 could indeed induce the generation of ROS (Fig. 6b, c). Thus, we speculated that ABHD2 might affect the development of HCC through the ROS produced by FFA metabolism. Expectedly, the silence of ABHD2 remarkably increased the apoptotic rate in SMMC-7721 and MHCC97H cells (Fig. 6d–f). The result of western blot further showed that after ABHD2 knocking down, the expression levels of p53, C-caspase3 and Bax were elevated, while the expression level of antiapoptotic gene Bcl-2 was reduced (Fig. 6g and Supplementary Fig. 4c). In addition, CCK-8 and colony formation assay showed that ABHD2 deficiency also resulted in the inhibition of cell proliferation (Supplementary Fig. 4d, e). Then, we aimed to investigate the role of ROS in ABHD2-suppressed apoptosis. We carried out flow cytometry, qRT-PCR, and Western blot assays in ABHD2-overexpressed Huh-7 cells upon the treatment of ROS scavenger N-Acetyl-L-cysteine (NAC). The results showed that NAC treatment could alleviate the inhibition of apoptosis induced by ABHD2 overexpression (Supplementary Fig. 5), suggesting that ABHD2 inhibits apoptosis in an ROS-dependent manner.

TDP-43 facilitates lipid metabolism via ABHD2 to suppress apoptosis in vitro

Next, we wondered whether TDP-43 could modulate lipid metabolism by ABHD2 to suppress apoptosis. First, we performed TG assays in SMMC-7721 and MHCC97H cells. Notably, TDP-43 knockdown induced the accumulation of TG while elevation of ABHD2 could alleviate this phenomenon (Supplementary Fig. 6a). Furthermore, when TDP-43 was silenced, the FFA content was decreased (Fig. 7a). However, overexpression of ABHD2 could efficiently relieve the decrease of FFA induced by TDP-43 deficiency (Fig. 7a). Determination of ROS level also manifested the rescue effect of ABHD2 on TDP-43 deletion-induced decrease of ROS (Fig. 7b, c). Then, we aimed to confirm the role of ABHD2 in TDP-43-regulated cell apoptosis. Expectedly, ABHD2 markedly suppressed the apoptosis induced by the lack of TDP-43 (Fig. 7d, e). QRT-PCR and western blot further showed that ABHD2 disrupted the upregulation of p53 and C-caspase3 evoked by TDP-43 knockdown; TDP-43 deletion induced-downregulation of Bcl-2 and Ki67 was also improved by ABHD2 (Fig. 7f, g and Supplementary Fig. 6b). In addition, CCK-8 data uncovered that elevation of ABHD2 could improve the decline of cell proliferation induced by TDP-43 knockdown (Supplementary Fig. 6c). Considering that the anti-apoptotic effect of TDP-43 was mediated through ABHD2-associated lipid metabolism, we next evaluated the role of the metabolite FFA in TDP-43-inhibited apoptosis. We performed rescue experiments by FFA in SMMC-7721 cells with knockdown of TDP-43. Flow cytometry, qRT-PCR and Western blot assays showed that FFA treatment effectively reversed the apoptosis caused by TDP-43 deletion (Supplementary Fig. 6d–g). These findings indicate that TDP-43 is able to suppress apoptosis through ABHD2-mediated lipid metabolism.

TDP-43 facilitates lipid metabolism via ABHD2 to suppress apoptosis in vivo

Next, we constructed stable overexpression of ABHD2 cell lines based on MHCC97H-KD-TDP-43 and MHCC97H-Control cells. The above cells (MHCC97H-Control + vector, MHCC97H-KD-TDP-43 + vector and MHCC97H-KD-TDP-43 + ABHD2) were collected for subcutaneous tumor implantation in nude mice. After 42 days, the subcutaneous tumors of three groups were collected and the tumor weight was detected. The results showed that overexpression of ABHD2 effectively alleviated the inhibition of tumor growth caused by TDP-43 deletion (Fig. 8a–c). Examination of FFA content in mice tumors also manifested the same result: TDP-43 deletion induced-reduction of FFA could be rescued by ABHD2 overexpression (Fig. 8d). Then, the protein abundances of TDP-43, ABHD2, Ki67, C-caspase3, p53 and Bcl-2 in tumor tissues were detected by IHC staining. We observed that deletion of TDP-43 caused the downregulation of Ki67 and Bcl-2, and the upregulation of p53 and C-caspase3 in mice tumors in contrast to the control group (Fig. 8e, f). However, ABHD2 overexpression appreciably relieved the above phenomenon (Fig. 8e, f). Taken together, these findings disclose that TDP-43 can facilitate lipid metabolism by upregulating ABHD2, to inhibit apoptosis in HCC cells.

Discussion

Over the years, with the development of medicine, we have made considerable progress in the diagnosis and treatment of HCC; However, statistics have showed that almost 70% of patients recur within 5 years after operation³¹. Therefore, the exploration of strategies and targets for the treatment of HCC has never stopped. The poor prognosis of HCC is mainly related to the delay of diagnosis³². Study of biomarkers may provide more instructive information for the individualized diagnosis and/or prognosis of HCC. The role of TDP-43 in neurological diseases has been well studied, but its potential function in malignant tumors still needs to be explored. In our study, survival analysis manifested that the higher the expression level of TDP-43, the shorter the survival rate of HCC patients. Moreover, TDP-43 had been proved to inhibit apoptosis and promote proliferation in HCC cells, thus accelerating the malignant development of HCC. Our discovery is expected to provide a biomarker for the treatment of HCC, so as to be applied to the diagnosis and prognosis of patients.

To elucidate the mechanism of TDP-43 promoting HCC, we implemented high-throughput sequencing and found that TDP-43 was indeed closely related to the apoptotic pathway. Interestingly, KEGG analysis showed that metabolic pathways strongly responded to the changes in TDP-43 expression. Therefore, we suspected that TDP-43 was likely to suppress the apoptosis of HCC by affecting metabolic pathways. The further classification analysis of KEGG pathway discovered the close association between lipid metabolism and TDP-43. Lipids are critical to the cellular life as molecules for energy storage, membrane structure and signal transduction^33,34. So, we supposed whether TDP-43 modulated lipid metabolism-related gene in HCC. In order to confirm our speculation, we detected the expression of all metabolism-related genes among the differential downregulated genes (Top50) and observed that the lipid metabolism-related gene ABHD2 was most dramatically downregulated after TDP-43 silencing. ABHD2, as a member of the mammalian ABHD family, is a triacylglycerol lipase with ester hydrolysis ability²⁵. Conserved structural motifs shared by the members of ABHD family primarily play a role in lipid synthesis and degradation. In recent years, the ABHD family has emerged as a potential regulator of signal transduction and lipid metabolism³⁴. The above findings led us to investigate whether TDP-43 could modulate lipid metabolism via ABHD2. TG and FFA content examination displayed that TDP-43 enhanced the TG-originated production of FFA in an ABHD2-dependent manner. Fatty acid oxidation (FAO)-originated ROS maybe a major source of ROS and plays a crucial role in oxidative stress during FFA overload in the liver^35,36. By detecting intracellular ROS levels, we discovered TDP-43 was able to elevate the content of ROS through ABHD2. The production of ROS could activate multiple oncogenic signaling pathways and furthermore contribute to the pathogenesis of multiple diseases, including cancers^37,38. Expectedly, we found that ABHD2 could robustly attenuate the promotion of apoptosis induced by TDP-43 deletion. Moreover, FFA treatment also efficiently alleviate TDP-43 deficiency-caused apoptosis. These evidences revealed that with the help of ABHD2, TDP-43 regulated lipid metabolism, which had an impressive effect on tumor cell apoptosis.

Notably, few studies have addressed the role of ABHD2 in malignant tumors. It is reported that the expressions of ABHD2 in breast cancer and melanoma are obviously higher than those in normal tissues^39,40,41, but whether it has molecular functions in these two cancers is still unknown. The Obinata team has reported that ABHD2 is an androgen-responsive gene, and it can promote the growth and migration of prostate cancer⁴². However, in HCC, the expression and underlying function of ABHD2 remains to be elucidated. In this study, we first put forward that ABHD2 played a crucial role in inhibiting apoptosis and promoting proliferation in HCC. A study in 2009 found that increased apoptosis could be observed in ABHD2 gene deficient mice⁴³, which was consistent with our findings. In conclusion, our data suggested that ABHD2 had significance in tumor development and was expected to be a potential target for the precise treatment of HCC.

In the study of the mechanism of TDP-43 regulating ABHD2, we confirmed that TDP-43 bind to the site1 (UG-rich sequence1) to enhance the mRNA stability of ABHD2, thus upregulating ABHD2. Interestingly, we also found that ABHD2 had a certain effect on the expression of TDP-43. Western blot and qRT-PCR data displayed that the level of TDP-43 expression was upregulated after ABHD2 overexpression (Fig. 7f, g). Especially in the qRT-PCR experiment, ABHD2-induced upregulation of TDP-43 showed noticeable statistical significance. Therefore, we speculated that ABHD2 might be able to reversely regulate the expression of TDP-43. However, whether there was a positive feedback loop between TDP-43 and ABHD2 to jointly promote the development of HCC or other tumors is still unclear.

In summary, our study discloses a mechanism for TDP-43-promoted HCC progression (Fig. 9). As an RNA-binding protein, TDP-43 can bind to the mRNA 3ʹUTR of lipid metabolism-related gene ABHD2, enhance the stability of ABHD2 mRNA, and then upregulate ABHD2. Elevated-ABHD2 catalyzes the metabolic process of TG to FFAs, thus promoting the β-oxidation pathway and increasing the production of ROS, finally resulting in the suppression of apoptosis and facilitation of proliferation in HCC. Our study provides a theoretical basis for elucidating the role of RNA-binding proteins in the promotion of malignance. Meanwhile, TDP-43/ABHD2 can be used as potential target, which has important application value in the precise treatment of HCC.

**Fig. 9: Schematic diagram of TDP-43 suppressing apoptosis by modulating ABHD2 in HCC.**

Methods

Plasmid construction and small interference RNA (siRNA)

Using the mRNA extracted from SMMC-7721 cells as the template, the coding region sequence (CDS) of TDP-43 was amplified by RT-PCR. During amplification, the enzyme digestion sites were introduced. The PCR products and vector pEGFP-C2 were double digested, respectively. Then, the PCR products were connected with pEGFP-C2 by T4 DNA ligase. Finally, the recombinant plasmid pEGFP-TDP-43 was used for exogenous overexpression of TDP-43. The pCMV3-ABHD2 expression plasmid was purchased form Sino Biological (China, HG14770-CF) and was used for ABHD2 overexpression. The 3ʹUTR of ABHD2 was amplified by PCR using specific primers and inserted into the pGL3-Control vector to generate the pGL3-ABHD2-3ʹUTR (WT). Then, two sites rich in UG sequence were separately deleted to construct two different ABHD2 3ʹUTR mutants (Del-1 and Del-2). All siRNAs used in this study were generated by RiboBio (Guangzhou, China), and the sequences of siRNAs were listed in the Supplementary Table 1. The primer sequences used in ABHD2 3ʹUTR construction were shown in Supplementary Table 3.

Western blot assay

Total proteins were extracted by RIPA buffer (Beyotime, China) containing 1nmol/L PMSF (Beyotime). The proteins were resolved by SDS-PAGE and then transferred on a polyvinylidene difluoride membrane (GE Healthcare Life Sciences, USA). After incubation with 5% skimmed milk at room temperature for 2 h, the blot was hybridized with the primary antibody at 4 °C overnight. After washing by TBST three times, the blot was incubated with the secondary antibody (Beyotime, A0208, A0216, dilution: 1:1000) at room temperature for 1 h. After adding the enhanced chemiluminescence (NCM Biotech, China), the immunoblots were obtained using Azure600 (azure biosystems, USA). The primary antibodies used in this study were GAPDH (Abcam, UK, ab181602, dilution: 1:5000), TDP-43 (Abcam, ab190963, dilution: 1:2000), ABHD2 (absin, China, abs140798, dilution: 1:1000), Cleaved-caspase3 (Cell Signaling, USA, #9664, dilution: 1:2000), p53 (Proteintech, USA, 10442-1-AP, dilution: 1:5000), Bax (Cell Signaling, #5023, dilution: 1:1000), Bcl-2(Abcam, ab182858, dilution: 1:2000), Ki67 (Abcam, ab16667, dilution: 1:1000).

Flow cytometry assay

In total, 1×10 ⁵ cells were plated into 6-well plates and were harvested after transfection for 48 h. After washing with precooled PBS, the binding buffer was added to resuspend cells. Subsequently, dye the cells with 5 μl Annexin V-FITC and 5 μl propidium (KeyGen Biotech, China). Within 1 h, the apoptotic cells were detected by flow cytometry. Three replicates were set in each group.

Determination of FFA content

To evaluate intracellular lipid metabolism, cells were seeded on a 6-well plate and collected after transfection for 48 h. According to the manufacturer’s operating instructions, the FFA levels were determined using a Free Fatty Acid Quantification Kit (CoMIN, China). For tumor metabolism analysis, the mice tumor tissues need to be ground in an ice bath first, and then assayed for FFA content according to the instructions.

Immunohistochemistry (IHC) staining

Paraffin-embedded xenograft sections were used for TDP-43 (Servicebio, China, GB112160, dilution: 1:400), ABHD2 (absin, abs140798, dilution: 1:200), C-caspase3 (Servicebio, GB11532, dilution: 1:500), Bcl-2 (Servicebio, GB113375, dilution: 1:500), and p53 (Servicebio, GB111740, dilution: 1:500) staining analysis. The antibody of Ki67 used in this experiment was purchased from Abcam (ab15580, dilution: 1:200). After deparaffinized and rehydrated, sections were laid in EDTA solution (pH9.0) for antigen retrieval by boiling in microwave oven for 8 min on medium heat. The slides were naturally cooled before treating with 3% H₂O₂ for 10 min. Sections were blocked in 10% normal goat serum for 30 min at room temperature, and then incubated overnight with indicated primary antibody at 4°C. After three washes with PBS, the slides were hybridized with the secondary antibody (Servicebio, GB23303, dilution: 1:200) for 50 min at room temperature. Finally, diaminobenzidine (DAB) (servicebio) was used for color development. After counterstaining with hematoxylin, dehydrate the slides and seal with neutral gum (Solarbio, China). Image J software was used for staining analysis.

Tissue microarray analysis

HCC tissue microarray (No. live c-1401) was purchased from Servicebio. It contains 32 cases of HCC tissues and paired non-tumor tissues, including hepatocellular carcinoma, cholangiocarcinoma, and mixed hepatocellular carcinoma-cholangiocarcinoma with different degrees of differentiation. See Supplementary table 4 for patient records. The tissue microarray was stained by IHC, and the staining analysis was performed by Image J. The grading criteria for the staining levels of TDP-43 and ABHD2 were as follows: During microscopic observation, 5 different sights were randomly chosen for staining evaluation. The assessment was divided into two parameters: positive staining rate and staining intensity. For the staining rate, 0% stained = 0; 1–29% stained = 1; 30–65% stained = 2; 66–100% stained = 3. For the staining intensity, negative = 0; low = 1; moderate = 2; high = 3. Finally, multiply the scores of the above two parameters. When the result is less than 1, the final score is recorded as 0 (non-staining); result is 1, 2 or 3, the final score is recorded as 1 (weak staining); result is 4 or 6, the final score is 2 (moderate staining); result is 9, the final score is 3 (intense staining). The heat map is drawn and analyzed according to the above final scores.

Xenograft

Beijing Vital River Laboratory Animal company provided the BALB/c Nude mice (carrying Foxn1^nu mutation) for the xenograft experiment. The experiment followed the guidelines of the Ethics Committee of Xinxiang Medical University, and nude mice were fed according to the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. 6- to 8-week-old male mice were grouped randomly (n = 5 or 6). After growing to the logarithmic growth phase, the cells were collected and implanted subcutaneously in the right shoulder of each nude mouse. One week after subcutaneous inoculation, the volume of tumor was measured every three days, the weight of mice was recorded as well. Six weeks later, the nude mice were euthanized and dissected, and the tumor was photographed and weighed. Then, the tumor tissues were analyzed by immunohistochemistry and free fatty acid content in order to analyze the related proliferation, apoptosis and metabolic indexes.

RNA-sequencing (RNA-seq)

MHCC97H-KD-TDP-43 and MHCC97H-Control cells were used as the research objects, and there were three replicates in each set. The above cells were grown to logarithmic phase and were collected to extract RNA. The concentration and purity of RNA were measured. Then, the specimen was sent to HuaDa BGI (China) for RNA-seq. BGI is responsible for the construction of mRNA library and analysis of transcriptome data. For detailed protocols, please visit the official website of BGI. RNA-seq reads were quantified as Fragments Per kilobase Million.

RNA immunoprecipitation (RIP)

The RIP assay was conducted to examine the interaction of TDP-43 and ABHD2 mRNA. Briefly, HCC cells were gathered by centrifugation and then lysed with RIP lysis buffer containing RNAase inhibitor. The protein A + G agarose beads (Millipore, USA) were re-suspended and incubated with TDP-43 antibody or control IgG for 1 h. Next, the cell lysate was incubated with the above-prepared agarose beads at 4°C overnight. After repeated cleaning with NT-2 buffer for 6–8 times, added protease K buffer into agarose beads and water bath at 55 °C for 30 min to remove protein. Finally, NT-2 buffer was added and immunoprecipitated RNA was extracted with Trizol reagent for qRT-PCR analysis.

Statistics and reproducibility

All replicates displayed in this paper are biological replicates; technical replicates (usually three) were performed and used to generate the means for each biological replicate. The sample sizes and number of replicates were indicated in the figure legends. Graph pad prism 8.0 (San Diego, USA) was used for statistical analysis. The statistical significance was evaluated by comparing the mean of three biologically independent experiments using a 2-tailed student’s t-test. Error bars represent ±s.d. A value of P < 0.05 was considered statistically significant. ***P < 0.001, **P < 0.01, *P < 0.05. The correlations between TDP-43 expression with the relapse-free survival and overall survival were separately analyzed via the online resource Kaplan-Meier Plotter (https://kmplot.com/analysis/index.php?cancer=liver_rnaseq&p=service) and GEPIA (http://gepia.cancer-pku.cn/). In the analysis of HCC tissue microarray, the correlation between TDP-43 and ABHD2 expression was determined according to Pearson’s chi-square independent test.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The source data underlying the graphs presented in the main figures are shown as Supplementary data 1. Uncropped blots can be found in Supplementary Figs. 7–10. RNA-seq data are available in SRA database of NCBI as PRJNA855537. Plasmids for TDP-43 expression and ABHD3-3ʹUTR are deposited at Addgene (Accession numbers 190093, 190094, 190095 and 190096). All other data supporting the findings of the study are available within the paper and Supplementary information. Data relating to Supplementary figures are available from Zhi-fa Shen or Bo-wen Liu upon reasonable request.

References

Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R. & Zhou, J. Targeted therapy for hepatocellular carcinoma. Signal Transduct. Target Ther. 5, 146 (2020).
Article PubMed PubMed Central Google Scholar
Kulik, L. & El-Serag, H. B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156, 477–491.e471 (2019).
Article PubMed Google Scholar
Kim, E. & Viatour, P. Hepatocellular carcinoma: old friends and new tricks. Exp. Mol. Med. 52, 1898–1907 (2020).
Article CAS PubMed PubMed Central Google Scholar
Brown, G. Oncogenes, proto-oncogenes, and lineage restriction of cancer stem cells. Int. J. Mol. Sci. 22, 9667 (2021).
Chhangani, D., Martin-Pena, A. & Rincon-Limas, D. E. Molecular, functional, and pathological aspects of TDP-43 fragmentation. iScience 24, 102459 (2021).
Article CAS PubMed PubMed Central Google Scholar
Klim, J. R., Pintacuda, G., Nash, L. A., Guerra San Juan, I. & Eggan, K. Connecting TDP-43 Pathology with Neuropathy. Trends Neurosci. 44, 424–440 (2021).
Article CAS PubMed Google Scholar
Ou, S. H., Wu, F., Harrich, D., Garcia-Martinez, L. F. & Gaynor, R. B. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69, 3584–3596 (1995).
Article CAS PubMed PubMed Central Google Scholar
Buratti, E. & Baralle, F. E. Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci. 13, 867–878 (2008).
Article CAS PubMed Google Scholar
Costessi, L., Porro, F., Iaconcig, A. & Muro, A. F. TDP-43 regulates beta-adducin (Add2) transcript stability. RNA Biol. 11, 1280–1290 (2014).
Article PubMed Google Scholar
Kawahara, Y. & Mieda-Sato, A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc. Natl Acad. Sci. USA 109, 3347–3352 (2012).
Article CAS PubMed PubMed Central Google Scholar
Chen, X. et al. TDP-43 regulates cancer-associated microRNAs. Protein Cell 9, 848–866 (2018).
Article CAS PubMed Google Scholar
Kawakami, I., Arai, T. & Hasegawa, M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 138, 751–770 (2019).
Article CAS PubMed PubMed Central Google Scholar
Cohen, T. J., Lee, V. M. & Trojanowski, J. Q. TDP-43 functions and pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 17, 659–667 (2011).
Article CAS PubMed PubMed Central Google Scholar
Ke, H. et al. Loss of TDP43 inhibits progression of triple-negative breast cancer in coordination with SRSF3. Proc. Natl Acad. Sci. USA 115, E3426–E3435 (2018).
Article CAS PubMed PubMed Central Google Scholar
Zeng, Q. et al. Identification of TDP-43 as an oncogene in melanoma and its function during melanoma pathogenesis. Cancer Biol. Ther. 18, 8–15 (2017).
Article CAS PubMed Google Scholar
Yang, L. T. et al. Restoration of Mal overcomes the defects of apoptosis in lung cancer cells. PLoS One 15, e0227634 (2020).
Article CAS PubMed PubMed Central Google Scholar
Park, Y. Y. et al. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 58, 182–191 (2013).
Article CAS PubMed Google Scholar
Koundouros, N. & Poulogiannis, G. Reprogramming of fatty acid metabolism in cancer. Br. J. Cancer 122, 4–22 (2020).
Article CAS PubMed Google Scholar
Alves-Bezerra, M. & Cohen, D. E. Triglyceride metabolism in the liver. Compr. Physiol. 8, 1–8 (2017).
PubMed PubMed Central Google Scholar
Hu, B., Lin, J. Z., Yang, X. B. & Sang, X. T. Aberrant lipid metabolism in hepatocellular carcinoma cells as well as immune microenvironment: A review. Cell Prolif. 53, e12772 (2020).
Article PubMed PubMed Central Google Scholar
Pope, E. D. 3rd et al. Aberrant lipid metabolism as a therapeutic target in liver cancer. Expert Opin. Ther. Targets 23, 473–483 (2019).
Article CAS PubMed PubMed Central Google Scholar
Choudhary, G. S., Al-Harbi, S. & Almasan, A. Caspase-3 activation is a critical determinant of genotoxic stress-induced apoptosis. Methods Mol. Biol. 1219, 1–9 (2015).
Article CAS PubMed Google Scholar
Lukavsky, P. J. et al. Molecular basis of UG-rich RNA recognition by the human splicing factor TDP-43. Nat. Struct. Mol. Biol. 20, 1443–1449 (2013).
Article CAS PubMed Google Scholar
Bhardwaj, A., Myers, M. P., Buratti, E. & Baralle, F. E. Characterizing TDP-43 interaction with its RNA targets. Nucleic Acids Res 41, 5062–5074 (2013).
Article CAS PubMed PubMed Central Google Scholar
M, N. K. et al. Molecular characterization of human ABHD2 as TAG lipase and ester hydrolase. Biosci Rep. 36 (2016).
Arab, J. P., Arrese, M. & Trauner, M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev. Pathol. 13, 321–350 (2018).
Article CAS PubMed Google Scholar
Beloribi-Djefaflia, S., Vasseur, S. & Guillaumond, F. Lipid metabolic reprogramming in cancer cells. Oncogenesis 5, e189 (2016).
Article CAS PubMed PubMed Central Google Scholar
Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813–820 (2001).
Article CAS PubMed Google Scholar
Sangineto, M. et al. Lipid metabolism in development and progression of hepatocellular carcinoma. Cancers. 12, 1419 (2020).
Sullivan, L. B. & Chandel, N. S. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2, 17 (2014).
Article PubMed PubMed Central Google Scholar
Villanueva, A. et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140, 1501–1512.e1502 (2011).
Article CAS PubMed Google Scholar
Patel, N., Yopp, A. C. & Singal, A. G. Diagnostic delays are common among patients with hepatocellular carcinoma. J. Natl Compr. Canc Netw. 13, 543–549 (2015).
Article PubMed PubMed Central Google Scholar
Huang, C. & Freter, C. Lipid metabolism, apoptosis and cancer therapy. Int. J. Mol. Sci. 16, 924–949 (2015).
Article CAS PubMed PubMed Central Google Scholar
Lord, C. C., Thomas, G. & Brown, J. M. Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. Biochim Biophys. Acta 1831, 792–802 (2013).
Article CAS PubMed PubMed Central Google Scholar
Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic. Biol. Med. 152, 116–141 (2020).
Article CAS PubMed Google Scholar
Tahara, E. B., Navarete, F. D. & Kowaltowski, A. J. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species generation. Free Radic. Biol. Med 46, 1283–1297 (2009).
Article CAS PubMed Google Scholar
Koundouros, N. & Poulogiannis, G. Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. Front Oncol. 8, 160 (2018).
Article PubMed PubMed Central Google Scholar
Yang, Y. et al. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J. Cell Physiol. 231, 2570–2581 (2016).
Article CAS PubMed Google Scholar
Richardson, A. L. et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121–132 (2006).
Article CAS PubMed Google Scholar
Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008).
Article CAS PubMed Google Scholar
Talantov, D. et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234–7242 (2005).
Article CAS PubMed Google Scholar
Obinata, D. et al. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration. Eur. J. Cancer 57, 39–49 (2016).
Article CAS PubMed Google Scholar
Jin, S. et al. Age-related pulmonary emphysema in mice lacking alpha/beta hydrolase domain containing 2 gene. Biochem Biophys. Res Commun. 380, 419–424 (2009).
Article CAS PubMed Google Scholar

Download references

Acknowledgements

This work was supported by the National Natural Scientific Foundation of China (Grant NO. 81902982), the Science and Technology Key Project of Henan province, China (Grant NO. 212102310179), the Major project of Zhejiang Provincial Natural Science Foundation (Grant NO. LZ22H160007), and the Natural Science Foundation of Henan Province (Grant NO. 222300420264).

Author information

These authors contributed equally: Bo-wen Liu, Xiang-yun Wang, Jin-ling Cao.
These authors jointly supervised this work: Bo-wen Liu, Zhi-fa Shen.

Authors and Affiliations

Henan Key Laboratory of Immunology and Targeted Drugs, School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, PR China
Bo-wen Liu, Xiang-yun Wang, Jin-ling Cao, Lu-lu Chen, Yi-lei Wang, Bing-qian Zhao, Jia Zhou & Zhi-fa Shen

Authors

Bo-wen Liu
View author publications
You can also search for this author in PubMed Google Scholar
Xiang-yun Wang
View author publications
You can also search for this author in PubMed Google Scholar
Jin-ling Cao
View author publications
You can also search for this author in PubMed Google Scholar
Lu-lu Chen
View author publications
You can also search for this author in PubMed Google Scholar
Yi-lei Wang
View author publications
You can also search for this author in PubMed Google Scholar
Bing-qian Zhao
View author publications
You can also search for this author in PubMed Google Scholar
Jia Zhou
View author publications
You can also search for this author in PubMed Google Scholar
Zhi-fa Shen
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

B.L.: Conceptualization, Methodology, Formal analysis, Investigation, Writing-original draft, Visualization, Funding acquisition; X.W. and J.C.: Methodology, Formal analysis, Investigation, Writing-review & editing; L.C., Y.W., B.Z. and J.Z.: Investigation, Validation.; Z.S.: Conceptualization, Supervision, Project administration, Writing-review & editing, Funding acquisition.

Corresponding authors

Correspondence to Bo-wen Liu or Zhi-fa Shen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Communications Biology thanks Zhuqing Ren and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Eve Rogers.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Peer Review File

Supplementary Information

Description of Additional Supplementary Files

Supplementary Data 1

Reporting Summary

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Liu, Bw., Wang, Xy., Cao, Jl. et al. TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma. Commun Biol 5, 816 (2022). https://doi.org/10.1038/s42003-022-03788-w

Download citation

Received: 10 February 2022
Accepted: 02 August 2022
Published: 13 August 2022
DOI: https://doi.org/10.1038/s42003-022-03788-w

This article is cited by

Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma
- Hao Zhang
- Juntang Lin
- Badrul Hisham Yahaya
Journal of Cancer Research and Clinical Oncology (2024)
circPSD3 is a promising inhibitor of uPA system to inhibit vascular invasion and metastasis in hepatocellular carcinoma
- Liangliang Xu
- Peng Wang
- Mingqing Xu
Molecular Cancer (2023)
Implications of TDP-43 in non-neuronal systems
- Hao Ke
- Kang Liu
- Limin Zhao
Cell Communication and Signaling (2023)
Roles of RNA-binding proteins in neurological disorders, COVID-19, and cancer
- Daniel Ruben Akiola Sanya
- Claudia Cava
- Djamila Onésime
Human Cell (2022)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.